Main Menu

Target Evaluation & Molecular Therapeutics Team

Dr Olivia Rossanese’s team is investigating new targets to support the discovery of novel therapeutics to treat cancer. The team is also defining the molecular and genetic factors governing a cancer’s sensitivity to treatment with new drugs, to guide their clinical use.

Team leader

Dr Olivia  Rossanese

Dr Olivia Rossanese

Dr Olivia Rossanese is Head of Biology in the Cancer Research UK Cancer Therapeutics Unit within the Division of Cancer Therapeutics. She is investigating new therapeutic targets for the treatment of cancer and examining the molecular consequences of their inhibition in cancer cells and tumours.

ORCID 0000-0002-1262-9522

Team members

Dr Michael Bright
Dr Michael Bright
Higher Scientific Officer

I am a drug discovery biologist, specialising in the biology of B cell malignancies. I am working on gene regulation networks that control tumour plasticity and cell state, reprogramming cancer cells to commit to terminal differentiation or cell death using innovative compounds discovered at ICR.

 LeAnne Carmichael
LeAnne Carmichael
Higher Scientific Officer

My research interests lie within translational cancer research to develop better therapeutic interventions for patients. Using a variety of cell and molecular biology techniques, I provide pre-clinical biological support for select drug discovery programmes within the Cancer Therapeutics Unit.

 Selby De Klerk
Selby De Klerk
Scientific Officer

I joined the team in 2017. I perform compound screening in cell-based assays and contribute to biological target validation as part of the BCL6 drug discovery project. I am interested in deciphering the molecular mechanisms driving compound activity in cells. I am also an active participant in public engagement, helping to communicate the work of the ICR.

 Paul Eve
Paul Eve
Senior Scientific Officer

I have worked at the ICR for over 15 years. I have worked on a number of drug discovery projects, including performing pre-clinical biological target validation for the CHK1 and AKT programmes; both of which produced clinical candidates. In my current work I have been pioneering molecular biology techniques to use as a tool for new drug target validation.

 Caitlin McCarthy
Caitlin McCarthy
PhD Student

I joined the team in 2016 to start my PhD. I am investigating how APOBEC enzymes contribute to mutational load and heterogeneity in cancer.

Dr  Daniel Miller
Dr Daniel Miller
Postdoctoral Training Fellow

I am a Postdoctoral Training Fellow studying the mechanism of action of BCL6 degrader compounds, using a combination of cell and molecular biology techniques.

 Barbara Sgorlon
Barbara Sgorlon
Personal Assistant

I am a PA and Admin Assistant within the Division of Cancer Therapeutics. I contribute to the team with my expertise in administrative support so that team leader and members can focus their time and energies on researching innovative solutions for cancer treatment.

Dr Dalia Tarantino
Dr Dalia Tarantino
Postdoctoral Training Fellow

I am a Postdoctoral Training Fellow evaluating the targeting of BCL6 in leukaemias and solid tumours.

Dr Mike Walton
Dr Mike Walton
Postdoctoral Scientist

I have worked at the ICR for over 25 years as a Post-doctoral Scientist, during which I have contributed to a number of successful drug discovery projects including CHK1, HSP90 and AKT. In the team, I am interested in understanding the molecular mechanisms behind biological responses to genotoxic agents, and how these may be therapeutically exploited.

 Fiona Want
Fiona Want
PhD Student

I joined the team in 2017 as a PhD student. I am currently investigating the role of APOBEC proteins in driving heterogeneity, evolution and drug resistance in bladder cancer.